| Drug ID: | Drug49 |
|---|---|
| Drug Name: | Vancomycin |
| CID: | 14969 |
| DrugBank ID: | DB00512 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05376228, , NCT00355602, , NCT06582264, , NCT04968951, , NCT02765256, , NCT06794944, , NCT05370885, , NCT02618187, , NCT03759041 |
| Molecular Formula: | C66H75Cl2N9O24 |
| Molecular Weight: | 1449.2 g/mol |
| Isomeric SMILES: | C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H] |
| Synonyms: | VANCOMYCIN; 1404-90-6; Vancomicina; Vancomycine; Vancomycinum; vancomicin; HSDB 3262; Vancomycine [INN-French]; Vancomycinum [INN-Latin]; Vancomicina [INN-Spanish] |
| Phase 0: | 11 |
| Phase 1: | 47 |
| Phase 2: | 99 |
| Phase 3: | 97 |
| Phase 4: | 121 |
| Description: | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. [PubChem] |
Molecular Structure
No molecular structure data available
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt452 | 14969 | Vancomycin | 6610 | SMPD2 | Rattus norvegicus (Norway rat) | 30545405 | [ampicillin co-treated with neomycin co-treated with gentamicins co-treated with metronidazole co-treated with vancomycin] results in increased expression of SMPD2 protein |
| dt453 | 14969 | Vancomycin | 6611 | SMS | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SMS mRNA |
| dt454 | 14969 | Vancomycin | 9304 | SNORD22 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SNORD22 mRNA |
| dt455 | 14969 | Vancomycin | 6637 | SNRPG | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SNRPG mRNA |
| dt456 | 14969 | Vancomycin | 8835 | SOCS2 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SOCS2 mRNA |
| dt457 | 14969 | Vancomycin | 6648 | SOD2 | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SOD2 mRNA |
| dt458 | 14969 | Vancomycin | 6649 | SOD3 | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SOD3 mRNA |
| dt459 | 14969 | Vancomycin | 6652 | SORD | Mus musculus (house mouse) | 18930951 | Vancomycin results in increased expression of SORD mRNA |
| dt460 | 14969 | Vancomycin | 6659 | SOX4 | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SOX4 mRNA |
| dt461 | 14969 | Vancomycin | 6678 | SPARC | Mus musculus (house mouse) | 18930951 | Vancomycin results in decreased expression of SPARC mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06582264 | A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis | PHASE1 | RECRUITING | Microbiotica Ltd | Ulcerative Colitis | BIOLOGICAL: MB310|OTHER: Placebo|DRUG: Vancomycin | Details |
| NCT04968951 | Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC) | EARLY_PHASE1 | TERMINATED | Ari M Grinspan | Ulcerative Colitis|FMT|Fecal Microbiota Transplant | DRUG: Metronidazole|DRUG: Placebo|DRUG: Vancomyci… | Details |
| NCT03759041 | A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis | PHASE2 | TERMINATED | Seres Therapeutics, Inc. | Ulcerative Colitis | DRUG: Vancomycin Pre-Treatment|DRUG: Placebo for … | Details |
| NCT02618187 | A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis | PHASE1 | COMPLETED | Seres Therapeutics, Inc. | Ulcerative Colitis | DRUG: SER-287|DRUG: Placebo|DRUG: Placebo Pre-Tre… | Details |
| NCT02765256 | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease | PHASE2 | COMPLETED | University of Pennsylvania | Crohn's Disease | DRUG: Fluconazole|DRUG: Vancomycin|DRUG: Neomycin… | Details |
| NCT04014413 | Safety and Efficacy of Fecal Microbiota Transplantation | None | RECRUITING | Chinese University of Hong Kong | Crohn Disease|Ulcerative Colitis|Celiac Disease|I… | PROCEDURE: Fecal Microbiota Transplantation | Details |
| NCT05376228 | A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | Not Available | UNKNOWN | University Hospital Birmingham NHS Foundation Trust | Inflammatory Bowel Diseases; Primary Sclerosing C… | DRUG: Oral Vancomycin | Details |
| CTIS2023-507425-42-00 | A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - VanC-IT | PHASE2 | Not Recruiting | University Of Milano Bicocca | Primary Sclerosing Cholangitis MedDRA version: 2… | Product Name: , Product Code:SCP32734155, Pharmac… | Details |
| NCT05876182 | A Prospective, Randomized, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults and Young Adults (15-17 Years Old) Affected by Primary Sclerosing Cholangitis With or Without Inflammatory Bowel Disease | PHASE2 | Recruiting | University of Milano Bicocca | Primary Sclerosing Cholangitis;Liver and Intrahep… | Drug: Oral Vancomycin;Other: Placebo | Details |
| NCT06794944 | Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease | PHASE4 | NOT_YET_RECRUITING | Brigham and Women's Hospital | Inflammatory Bowel Disease (IBD)|Clostridioides D… | DRUG: Vancomycin (POC)|DRUG: Fidaxomicin | Details |
| EUCTR2022-000875-37-IT | A Prospective, Randomized, Placebo-controlled Clinical Trial of oral vancomycin in adults and young adults (15-17 years old) affected by Primary Sclerosing Cholangitis with or without Inflammatory Bowel Disease - Vancomycin in Primary Sclerosing Cholangitis in Italy | PHASE2 | Not Recruiting | UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | Primary Sclerosing Cholangitis MedDRA version: 2… | Trade Name: LEVOVANOX Product Name: LEVOVANOX Pro… | Details |
| NCT02464020 | A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | PHASE1 | Not recruiting | University of Minnesota | Primary Sclerosing Cholangitis;Inflammatory Bowel… | Drug: Vancomycin | Details |
| NCT01918813 | None | Not Available | Not recruiting | Chikara Tashiro | Inflammatory Bowel Disease;Hepatobiliary Disease;… | Drug: vancomycin, mupirocin ointment | Details |
| NCT01802073 | Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | PHASE3 | Not recruiting | Stanford University | Primary Sclerosing Cholangitis | Drug: Oral Vancomycin | Details |
| EUCTR2009-018034-11-SE | Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis - vanco-psc | Not Available | Authorised | Karolinska Institutet | Primary Sclerosing Cholangitis (PSC) is a progres… | Trade Name: Vancomycin Product Name: vancomycin P… | Details |
| NCT05370885 | VE202 in Patients with Mild-to-Moderate Ulcerative Colitis | PHASE2 | RECRUITING | Vedanta Biosciences, Inc. | Ulcerative Colitis|Colitis, Ulcerative | BIOLOGICAL: VE202|DRUG: Vancomycin Oral Capsule|O… | Details |
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Oral vancomycin is associated with less therapy intensification in adults with …
PMID: 40697439
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Case reports describe the use of oral vancomycin therapy (OVT) in adult patients with concomitant symptomatic inflammatory bowel disease …
Anti-Infection Efficacy, Osteogenesis Potential, and Biocompatibility of 3D Pri…
PMID: 40416730
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Given the limitations of traditional therapies, the treatment of infected bone defects (IBD) remains a great challenge. It is urgent to f…
Impact of vancomycin and Clostridioides difficile on the secretome and pathogen…
PMID: 40338351
Year: 2025
Relationship Type:
Mechanism
Score: 6.5
Clostridium innocuum, a member of the human gut microbiome with intrinsic resistance to vancomycin, has been increasingly associated with inflammator…
Vancomycin Therapy for Induction and Maintenance of Remission in a Patient with…
PMID: 40330085
Year: 2025
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Ulcerative colitis is a chronic inflammatory bowel disease that affects the colon. About 5% of ulcerative colitis patients also present…
[Are antibiotics immunomodulators? An attempt to use vancomycin in the treatmen…
PMID: 40274555
Year: 2025
Relationship Type:
Treatment
Score: 6.5
Primary sclerosing cholangitis (PSC) is a type of chronic idiopathic liver disease characterized by bile duct inflammation and concentric fibrosis. C…
Faecal microbiota transplantation to decolonize vancomycin-resistant Enterococc…
PMID: 40154780
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Faecal microbiota transplantation (FMT) has shown promise as a treatment for recurrent or refractory Clostridioides difficile infections.…
Fecal microbiota transplantation for vancomycin-resistant Clostridium innocuum …
PMID: 40074633
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Clostridium innocuum is a vancomycin-resistant pathobiome associated with poor clinical outcomes in inflammatory bowel disease (IBD). In …
Outcomes of oral vancomycin therapy in children with atypical ulcerative coliti…
PMID: 39938966
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Atypical ulcerative colitis (UC) presenting reverse gradient colitis, backwash ileitis, or rectal sparing and/or positive atypical antine…
Effectiveness and safety of oral vancomycin for the treatment of inflammatory b…
PMID: 39802627
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Inflammatory bowel disease (IBD) occurs in up to 70%-80% of patients with primary sclerosing cholangitis (PSC). Oral vancomycin therapy (…
Impact of prescribing vancomycin capsules vs liquid at discharge on readmission…
PMID: 39756415
Year: 2025
Relationship Type:
Association
Score: 6.5
PURPOSE: Clostridioides difficile infection (CDI) is a hospital-acquired infection commonly treated with oral vancomycin. An institutional policy aim…
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Dise…
PMID: 39673746
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV) …
[Vancomycin may be an effective attempt in primary sclerosing cholangitis: anti…
PMID: 39528315
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Primary Sclerosing Cholangitis(PSC) is a rare, chronic liver disease characterized by bile duct inflammation and concentric fibrogenesis. To date, th…
The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients …
PMID: 39495039
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Approximately 70% of primary sclerosing cholangitis (PSC) patients have inflammatory bowel disease (IBD). The IBD therapies currently use…
Oral vancomycin is associated with improved inflammatory bowel disease clinical…
PMID: 38462727
Year: 2024
Relationship Type:
Association
Score: 6.5
BACKGROUND: Data on oral vancomycin for primary sclerosing cholangitis (PSC)-associated inflammatory bowel disease (IBD) are limited. AIMS: Using dat…
Vancomycin in the treatment of inflammatory bowel disease: there is a role beyo…
PMID: 37882174
Year: 2024
Relationship Type:
Treatment
Score: 6.5
The development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many pati…
Evaluation of microbial and vancomycin treatments in ulcerative colitis in muri…
PMID: 37167242
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Despite the number of available therapies for ulcerative colitis (UC), severe side effects and high cost has limited their clinical appli…
The Antibacterial Effect, Biocompatibility, and Osteogenesis of Vancomycin-Nano…
PMID: 36974073
Year: 2023
Relationship Type:
Treatment
Score: 6.5
PURPOSE: The repair and treatment of infected bone defects (IBD) is a common challenge faced by orthopedic clinics, medical materials science, and ti…
Charge-reversible and biodegradable chitosan-based microgels for lysozyme-trigg…
PMID: 36585117
Year: 2023
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: High-dose drug administration for the conventional treatment of inflammatory bowel disease induces cumulative toxicity and serious side…
How frequent are vancomycin-resistant enterococci in patients with primary scle…
PMID: 36217097
Year: 2022
Relationship Type:
Treatment
Score: 6.5
In patients with primary sclerosing cholangitis (PSC), antimicrobial therapy with oral vancomycin (OV) is increasingly used to prevent progression of…
Microbiome Responses to Vancomycin Treatment in a Child With Primary Sclerosing…
PMID: 33997090
Year: 2021
Relationship Type:
Treatment
Score: 6.5
The therapeutic effects of off-label oral vancomycin in pediatric and adult primary sclerosing cholangitis (PSC)-inflammatory bowel disease, more com…